Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies-Reference-Cited by-同舟云学术

Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies

Published:2021-07-07 Issue:1S Volume:32 Page:S39-S44
ISSN:2162-5220
Container-title:Dermatitis
language:en
Short-container-title:Dermatitis

Author:

Kim Brian S.,Silverberg Jonathan I.,Ständer Sonja,Yosipovitch Gil,Simpson Eric L.,DiBonaventura Marco,Kerkmann Urs,Farooqui Saleem A.,Biswas Pinaki,Valdez Hernan,Cameron Michael C.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Dermatology,Immunology and Allergy

Reference25 articles.

1. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study;Ann Allergy Asthma Immunol,2018

2. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation;J Eur Acad Dermatol Venereol,2020

3. The impact of pruritus on quality of life: the skin equivalent of pain;Arch Dermatol,2011

4. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study;Acta Derm Venereol,2011

5. Clinical practice. Chronic pruritus;N Engl J Med,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations;Dermatology and Therapy;2024-07-02

2. Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice;Dermatology and Therapy;2023-07-23

3. Oral Janus kinase inhibitors for atopic dermatitis;Annals of Allergy, Asthma & Immunology;2023-05

4. Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient‐reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials;Journal of the European Academy of Dermatology and Venereology;2023-03-23

5. How to get rid of itching;Pharmacology & Therapeutics;2023-03